Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma

Abstract
CUTANEOUS T-cell lymphoma (CTCL) is a heterogeneous group of low-grade non-Hodgkin lymphomas that manifest primarily in the skin.1 Mean age at onset of disease is 50 to 56 years, and it is more common in men than in women (2.2:1.0) and in blacks than in whites (2:1).2,3 Approximately 1000 or more new cases of CTCL are diagnosed each year in the United States. The cause is unknown.3